Mounjaro®
Dual-agonist support that helps curb appetite, hunger, and cravings to drive substantial, sustained weight loss.
- ~22.5% average body weight loss
- Significant weight reduction
- Improves blood sugar levels
- Clinically proven weight loss

Does Ozempic cause anger issues? This question has emerged as more people use semaglutide for type 2 diabetes management. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for treating type 2 diabetes mellitus in adults. Whilst clinical trials and regulatory reviews have not established a direct link between Ozempic and anger or mood disturbances, some patients report subjective experiences of irritability or emotional changes. Understanding the evidence, recognising genuine side effects, and knowing when to seek medical advice are essential for anyone taking this medication. This article examines the relationship between Ozempic and mood symptoms, reviews recognised adverse effects, and provides guidance on managing mental wellbeing during treatment.
Summary: Current evidence does not support a direct causal link between Ozempic (semaglutide) and anger issues, though some patients report subjective mood changes that may relate to side effects or metabolic factors.
Ozempic (semaglutide) is a prescription medication licensed in the UK for the treatment of type 2 diabetes mellitus in adults. It is indicated as an adjunct to diet and exercise, either as monotherapy when metformin is not tolerated or as an add-on therapy with other diabetes medications. It belongs to a class of medicines called glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking the action of a naturally occurring hormone that regulates blood sugar levels.
The medication functions through several complementary mechanisms. Primarily, semaglutide stimulates insulin secretion from the pancreas when blood glucose levels are elevated, whilst simultaneously suppressing glucagon release—a hormone that raises blood sugar. Additionally, Ozempic slows gastric emptying, which helps reduce post-meal glucose spikes and promotes a feeling of fullness. This latter effect has contributed to its notable impact on weight reduction, leading to increased off-label use for weight management, though Wegovy (a higher-dose formulation of semaglutide) is the preparation specifically licensed for obesity treatment in the UK.
Ozempic is administered as a once-weekly subcutaneous injection, typically starting at 0.25 mg and gradually titrated upwards to therapeutic doses of 0.5 mg, 1 mg, or 2 mg, depending on individual glycaemic control and tolerability. Clinical trials have shown significant improvements in HbA1c levels, and the SUSTAIN-6 trial demonstrated cardiovascular safety, though it's important to note that Ozempic does not carry a specific UK licence for cardiovascular risk reduction.
It's worth emphasising that Ozempic is not indicated for type 1 diabetes or diabetic ketoacidosis. Whilst the medication has proven highly effective for its licensed indications, patients and healthcare professionals have raised questions about potential effects on mood and behaviour, including whether Ozempic might contribute to anger issues or emotional changes. Understanding the evidence base for such concerns is essential for informed prescribing and patient counselling.

The question of whether Ozempic directly causes anger issues or significant mood disturbances requires careful examination of available evidence. There is no official, established link between semaglutide and anger as a recognised adverse effect in the product's Summary of Product Characteristics (SmPC) or in large-scale clinical trials conducted prior to its UK approval.
Importantly, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) concluded in 2024 that current evidence does not support a causal link between GLP-1 receptor agonists, including semaglutide, and suicidal thoughts or self-injurious behaviour.
However, some patients have reported subjective experiences of irritability, mood swings, or emotional changes whilst taking GLP-1 receptor agonists, including Ozempic. These anecdotal reports, whilst not constituting clinical evidence, warrant consideration. It is important to distinguish between direct pharmacological effects and indirect consequences of treatment. For instance, the gastrointestinal side effects commonly associated with Ozempic—such as nausea, vomiting, and reduced appetite—may contribute to feelings of discomfort, fatigue, or irritability, which could manifest as mood changes.
Furthermore, rapid weight loss and significant dietary changes can affect energy levels, nutritional status, and psychological wellbeing. Some individuals may experience mood fluctuations related to caloric restriction or changes in eating patterns rather than the medication itself. Additionally, hypoglycaemia (low blood sugar), though less common with GLP-1 agonists than with insulin or sulphonylureas, can cause irritability, confusion, and mood changes when it does occur, particularly in patients taking concurrent diabetes medications.
The gut-brain axis—the bidirectional communication network between the gastrointestinal tract and central nervous system—represents another theoretical consideration. GLP-1 receptors are present in brain regions involved in mood regulation, though the clinical significance of semaglutide's central effects on emotional state remains unclear and this mechanism is speculative. Current evidence does not support a direct causal relationship between Ozempic and anger issues, but individual experiences may vary, and further research into the psychological effects of GLP-1 agonists would be valuable.
According to the MHRA-approved product information, Ozempic has a well-characterised side effect profile, with gastrointestinal symptoms being the most frequently reported adverse reactions. These include:
Nausea (very common, affecting more than 1 in 10 people)
Diarrhoea (very common)
Vomiting (common, affecting up to 1 in 10 people)
Constipation (common)
Abdominal pain (common)
Reduced appetite (very common)
These gastrointestinal effects typically occur during dose escalation and often diminish over time as the body adjusts to the medication. Starting at a low dose and gradually increasing, as per standard prescribing guidance, helps minimise these symptoms.
Hypoglycaemia is uncommon with Ozempic monotherapy but becomes more likely when combined with insulin or sulphonylureas. Symptoms include trembling, sweating, confusion, palpitations, and irritability—which could potentially be misattributed to mood changes rather than recognised as low blood sugar.
Other recognised adverse effects include:
Injection site reactions (redness, itching)
Fatigue (uncommon)
Dizziness (uncommon)
A modest increase in heart rate has been observed
Gallbladder disorders, including cholecystitis and cholelithiasis
Diabetic retinopathy complications (particularly in patients with pre-existing retinopathy and rapid improvement in glycaemic control)
Acute pancreatitis (uncommon)
Dysgeusia (taste disturbance)
Increases in pancreatic enzymes (amylase/lipase)
Serious allergic reactions, though rare, require immediate medical attention. If pancreatitis is suspected (severe, persistent abdominal pain, sometimes with vomiting), Ozempic should be discontinued immediately and urgent medical assessment sought.
Patients with pre-existing diabetic retinopathy should be monitored closely, as rapid improvement in blood glucose control may temporarily worsen retinopathy. Any new or worsening vision changes should be reported promptly.
The MHRA encourages healthcare professionals and patients to report any suspected adverse reactions through the Yellow Card Scheme (yellowcard.mhra.gov.uk), which helps identify previously unrecognised patterns of adverse events.
If you experience persistent or concerning mood changes whilst taking Ozempic, it is important to discuss these symptoms with your GP or diabetes specialist nurse. Whilst anger issues are not a recognised side effect, your healthcare team can help determine whether your symptoms might be related to the medication, underlying health conditions, or other factors.
Contact your GP or diabetes care team if you experience:
Persistent irritability, anger, or mood swings that are uncharacteristic for you
Symptoms of depression, including low mood, loss of interest in activities, or feelings of hopelessness
Anxiety or panic symptoms
Significant changes in sleep patterns
Difficulty concentrating or memory problems
Seek urgent mental health support if you have thoughts of self-harm or suicide by contacting your GP, NHS 111, or in an emergency, call 999 or go to A&E.
Seek same-day medical advice if you develop:
Symptoms of hypoglycaemia (trembling, sweating, confusion, irritability) that don't resolve with appropriate treatment
Severe or persistent abdominal pain, which could indicate pancreatitis (stop Ozempic immediately)
Signs of dehydration from persistent vomiting or diarrhoea
Sudden changes in vision or worsening of existing eye symptoms
Allergic reaction symptoms (rash, swelling, breathing difficulties) – call 999 or go to A&E if severe
Your healthcare provider may wish to review your overall medication regimen, assess for hypoglycaemia, check your nutritional status, and evaluate whether dose adjustment or alternative treatments might be appropriate. It's essential not to stop Ozempic abruptly without medical guidance for non-urgent issues, as this could affect your diabetes control.
Keeping a symptom diary noting when mood changes occur, their severity, and any potential triggers (such as timing relative to injections, meals, or blood sugar levels) can provide valuable information for your healthcare team. Remember that mood symptoms can have multiple causes, including diabetes itself, other medications, life stressors, or co-existing mental health conditions, all of which require proper assessment and management.
Maintaining good mental health whilst managing type 2 diabetes and taking medications like Ozempic involves a holistic approach that addresses both physical and psychological wellbeing.
Nutritional considerations are particularly important. The appetite suppression caused by Ozempic can lead to significantly reduced food intake, potentially resulting in nutritional imbalances that affect mood and energy levels. Ensure you're consuming a balanced diet with adequate:
Protein to maintain muscle mass and stable energy
Complex carbohydrates to prevent blood sugar fluctuations
Essential vitamins and minerals through a varied diet rich in fruits and vegetables
Adequate hydration, especially if experiencing gastrointestinal side effects
If you're concerned about nutritional deficiencies, discuss testing with your healthcare provider before considering supplements. Patients taking metformin alongside Ozempic may need vitamin B12 monitoring, as deficiency can contribute to fatigue and mood changes.
Consider requesting a referral to a dietitian through your GP or diabetes service for personalised nutritional guidance that accommodates both your diabetes management and the effects of Ozempic.
Blood glucose monitoring helps identify patterns that might affect mood. Even without frank hypoglycaemia, blood sugar fluctuations can influence how you feel emotionally. Work with your diabetes team to optimise your glucose control and adjust other medications if needed.
Lifestyle factors that support mental wellbeing include:
Regular physical activity – the UK Chief Medical Officers recommend 150 minutes of moderate-intensity activity weekly for adults
Adequate sleep (7-9 hours for most adults)
Stress management techniques such as mindfulness, meditation, or breathing exercises
Social connection and maintaining supportive relationships
Psychological support should be accessible if needed. Many diabetes services offer psychological support as part of integrated care. Your GP can refer you to NHS Talking Therapies for evidence-based psychological interventions if you're experiencing persistent mood difficulties.
Finally, maintain open communication with your healthcare team about all aspects of your treatment experience. Effective diabetes management encompasses not just glycaemic control but your overall quality of life and emotional wellbeing. If Ozempic is significantly affecting your mental health, alternative treatment options can be explored whilst ensuring your diabetes remains well controlled.
There is no established direct link between Ozempic and anger in clinical trials or regulatory reviews. However, indirect factors such as gastrointestinal discomfort, blood sugar fluctuations, or rapid dietary changes may contribute to mood symptoms in some individuals.
The most common side effects are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and reduced appetite. These typically occur during dose escalation and often improve over time as the body adjusts to the medication.
Contact your GP or diabetes care team if you experience persistent irritability, mood swings, symptoms of depression or anxiety, or any emotional changes that are uncharacteristic for you. Seek urgent help if you have thoughts of self-harm.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
Unordered list
Bold text
Emphasis
Superscript
Subscript